defective drug lawyers baltimore, product liability, medical malpractice lawyers maryland, low testosterone therapy

European Union Agrees with FDA, Testosterone Therapy Is Too Risky for All

December 15th, 2014

The leading Medical Associations in the United States and European Union have reached a consensus on therapies promising to treat low levels of testosterone in older men, a condition also known as “Low-T.” The U.S Food and Drug Administration (FDA) has already issued warnings about the use of Testosterone therapy treatments, advising consumers that the medications significantly raise the risk of serious blood clot and cardiac conditions. The European Union’s European Medicines Agency (EMA) reached a decision in November agreeing that it is best to limit use of Testosterone drugs to men with actual medical conditions preventing the release of normal levels of the hormone.

The decisions by the governing American and European medical agencies both discourage the so called “lifestyle” use of Testosterone therapy. The FDA voted by a margin of 14-1 back in September to restrict the use of Testosterone therapy drugs to men who have an actual medical condition, such as a tumor or genetic disorder, restricting the body’s normal release of Testosterone.  The EMA’s November decision aligns with this assessment by the FDA, noting that “Testosterone levels naturally fall somewhat with age, but restoration of these levels in healthy older men is not an authorized use of the medicine in the EU.”

Review of these products has come on the heels of several lawsuits filed by otherwise healthy men who suffered heart attacks or strokes following “lifestyle” use of testosterone products. “Lifestyle” uses of the products, which promise middle aged men a myriad of overall health benefits including improved energy levels, vitality and muscle tone, were marketed improperly by the testosterone product manufactures as safe and effective and did not recognize the potential cardiac risks.

The men involved in the lawsuits, aged 50 to 63, all claim to have suffered either heart attacks or strokes after taking the medication for “lifestyle” purposes. The plaintiffs also state that they were not properly informed of the medication’s risks prior to starting treatment, and are now paying the price for the manufacturer’s negligence.

If you or a loved one has suffered a heart attack, stroke, or pulmonary embolism after taking testosterone therapy, you may be entitled to compensation. Contact the experienced Defective Drug and Personal Injury attorneys at The Yost Legal Group at 1-800-YOST-LAW (967-8529).

Cases involving claims of injury or wrongful death due to dangerous drugs can be complex, but The Yost Legal Group works with a network of nationally recognized medical experts to establish fault and demand compensation through the courts for you and your family.

Call The Yost Legal Group today to speak with a Baltimore Defective Drug and Personal Injury attorney for a free consultation about your case. Our compassionate team of attorneys is prepared to explain your legal options.

The Yost Legal Group: Experienced Lawyers Dedicated to Protecting Your Rights.

AbbVie Hit with $150M Verdict in “Low-T” Trial

The first jury verdict in a series of bellwether trials involving the testosterone treatment AndroGel is in. The jury found that the manufacturer of the gel, AbbVie, should pay $150 million in punitive damages to Oregon resident Jesse Mitchell. After seeing a commercial about AndroGel and using the product for 4 years, Mr. Mitchell suffered a nearly fatal heart attack. He testified that he would not have used the drug if AbbVie had properly warned…

Read More »

First Testosterone Gel Trial to Begin in June

The first of seven multidistrict litigation (MDL) trials involving testosterone therapy gel products begins on June 5, 2017 in the U.S District Court for the Northern District of Illinois.  About 7,000 individual cases have been filed in this MDL. The Plaintiffs allege that over a dozen pharmaceutical companies unethically and aggressively marketed testosterone replacement therapy drugs to treat symptoms of normal male aging. AbbVie Inc. and Abbott Laboratories face most of the claims in the…

Read More »

FDA Announces Labeling Change for Low Testosterone Medications; Warns of Increased Risk of Heart Attack and Stroke with Use

The Food and Drug Administration (FDA) recently announced that they will be increasing restrictions on the labeling and sale of medication aimed at treating low levels of testosterone in adult men. For years, drug manufacturers have marketed medications such as Androgel, Axiron, and many others, as a “cure” for many of the symptoms associated with the normal aging process of adult men. According to these advertisements, problems such as lowered libido, erectile dysfunction, decreased energy…

Read More »

Low Testosterone Therapy is Causing Serious Adverse Reactions

Testosterone lawsuits are being filed throughout the country.  The Yost Legal Group defective drugs lawyers are actively investigating testosterone lawsuits for heart attack, stroke, pulmonary embolism and death. Reliable scientific studies confirm Testosterone supplementation dramatically increases the risk of these side effects in men who are healthy or have a prior heart condition. If your loved one has suffered heart attack, stroke, blood clot or death after initiating testosterone therapy, call the experienced testosterone lawyers…

Read More »